Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

Key Takeaways The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.Verizon Communications shares rose after the telecom ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...

Meanwhile, the average price target clocks in at $153.33 and implies shares will appreciate by 82.5% over the next 12 months. (See SRPT stock analysis on ... Is Sarepta Stock Worth Buying After ...

Despite A Q4 Miss Sarepta Therapeutics Stock Could ... at the current price of $87, SRPT stock has already halved from the ... This news last week led to a 50% plunge from levels of close to $ ...

Our dashboard, ‘What Factors Drove 62% Change In Sarepta Therapeutics Stock between 2017 and now?‘, has the underlying numbers. Sarepta’s P/S multiple expanded from 21x in 2017 to 25x in 2019.